Cyclerion Therapeutics, Inc. (CYCN)
Largest Insider Buys in Sector
CYCN Stock Price History Chart
CYCN Stock Performance
About Cyclerion Therapeutics, Inc.
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Cyclerion Therapeutics, Inc.
Over the last 12 months, insiders at Cyclerion Therapeutics, Inc. have bought $0 and sold $555,108 worth of Cyclerion Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Cyclerion Therapeutics, Inc. have bought $4.37M and sold $165,335 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 961,538 shares for transaction amount of $3M was made by Slate Path Capital LP (10 percent owner) on 2021‑06‑03.
List of Insider Buy and Sell Transactions, Cyclerion Therapeutics, Inc.
| 2024-11-21 | Sale | 10 percent owner | 357,880 11.132% | $1.55 | $555,108 | +127.46% | ||
| 2023-08-09 | Sale | director | 8 0.0003% | $3.40 | $27 | -10.12% | ||
| 2021-06-03 | 10 percent owner | 961,538 0.1301% | $3.12 | $3M | -39.01% | |||
| 2021-06-03 | Chief Executive Officer | 823,170 0.1171% | $3.28 | $2.7M | -39.01% | |||
| 2021-06-03 | director | 96,153 0.013% | $3.12 | $299,997 | -39.01% | |||
| 2021-05-06 | Chief Executive Officer | 302,000 0.0413% | $2.43 | $733,860 | +6.43% | |||
| 2021-05-05 | Chief Executive Officer | 398,001 0.0553% | $2.53 | $1.01M | +3.92% | |||
| 2021-05-04 | Chief Executive Officer | 300,000 0.0415% | $2.29 | $687,000 | +14.22% | |||
| 2021-02-25 | Sale | Chief Medical Officer | 2,637 0.0004% | $3.99 | $10,522 | -24.61% | ||
| 2021-02-25 | Sale | Chief Financial Officer | 1,824 0.0003% | $4.00 | $7,296 | -24.61% | ||
| 2020-12-28 | Sale | President and CSO | 20,107 0.0032% | $3.01 | $60,522 | +3.68% | ||
| 2020-11-09 | Chief Innovation Officer | 125,000 0.0199% | $2.53 | $316,250 | +27.42% | |||
| 2020-11-06 | Sale | Chief Financial Officer | 3,827 0.0006% | $2.52 | $9,644 | +27.42% | ||
| 2020-02-21 | Sale | Chief Financial Officer | 3,559 0.0007% | $5.12 | $18,222 | -16.49% | ||
| 2019-12-30 | Sale | President | 25,000 0.0839% | $2.48 | $62,000 | +42.59% | ||
| 2019-12-27 | Sale | President | 25,000 0.0917% | $2.55 | $63,750 | +51.97% | ||
| 2019-11-15 | Chief Innovation Officer | 125,000 0.4616% | $1.82 | $227,500 | +114.44% | |||
| 2019-11-08 | Sale | Chief Financial Officer | 3,922 0.0155% | $2.05 | $8,040 | +103.16% | ||
| 2019-04-08 | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% | |||
| 2019-04-08 | director | 626,117 0.1105% | $16.00 | $10.02M | -46.83% |
Insider Historical Profitability
| Slate Path Capital LP | 10 percent owner | 0 0% | $2.95 | 1 | 1 | <0.0001% |
| Hecht Peter M | Chief Executive Officer | 2047698 75.558% | $2.95 | 4 | 0 | <0.0001% |
| SCHULMAN AMY W | director | 604482 22.3048% | $2.95 | 1 | 0 | |
| Busch Andreas | Chief Innovation Officer | 254704 9.3983% | $2.95 | 2 | 0 | +70.93% |
| Currie Mark G | President and CSO | 251648 9.2856% | $2.95 | 1 | 3 | |
| Huyett William | Chief Financial Officer | 67590 2.494% | $2.95 | 0 | 3 | |
| Wright Christopher I | Chief Medical Officer | 42728 1.5766% | $2.95 | 0 | 1 | |
| Gjino Anjeza | Chief Financial Officer | 31599 1.166% | $2.95 | 0 | 1 | |
| MCGUIRE TERRANCE | director | 0 0% | $2.95 | 2 | 1 | <0.0001% |
Institutional Investor Ownership
| Slate Path Capital LP | $1.15M | 13.21 | 357,880 | 0% | +$0 | 0.02 | |
| Mfn Partners Management Lp | $542,272.00 | 6.25 | 169,460 | 0% | +$0 | 0.02 | |
| Tyndall Capital Partners L P | $527,286.00 | 6.08 | 164,777 | +0.21% | +$1,113.60 | 100 | |
| Fidelity Investments | $519,447.00 | 5.99 | 162,327 | -0.32% | -$1,670.40 | <0.0001 | |
| Artal Group S A | $444,656.00 | 5.13 | 138,955 | 0% | +$0 | <0.01 | |
| Geode Capital Management | $102,694.00 | 1.18 | 32,082 | +2.63% | +$2,634.41 | <0.0001 | |
| The Vanguard Group | $75,168.00 | 0.87 | 23,490 | 0% | +$0 | <0.0001 | |
| BlackRock | $54,941.00 | 0.63 | 17,169 | 0% | +$0 | <0.0001 | |
| UBS | $8,077.00 | 0.09 | 2,524 | +13.29% | +$947.22 | <0.0001 | |
| Morgan Stanley | $2,077.00 | 0.02 | 649 | -7.02% | -$156.81 | <0.0001 | |
| Group One Trading | $1,728.00 | 0.02 | 540 | 0% | +$0 | <0.0001 | |
| Royal Bank of Canada | $1,000.00 | 0.01 | 352 | +6.67% | +$62.50 | <0.0001 | |
| Wells Fargo | $48.00 | <0.01 | 15 | 0% | +$0 | <0.0001 | |
| Tower Research Capital | $106.00 | <0.01 | 33 | New | +$106.00 | <0.0001 | |
| Northwestern Mutual Wealth Management Co | $3.00 | <0.01 | 1 | 0% | +$0 | <0.0001 |